Is RCUS stock a strong buy?
Find the latest Arcus Biosciences, Inc. (RCUS) stock quote, history, news and other vital information to help you with your stock trading and investing.
What does RCUS stand for?
Apr 01, 2022 · Arcus Biosciences' stock was trading at $16.97 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, RCUS stock has increased by 98.6% and is now trading at $33.70. View which stocks have been most impacted by COVID-19.
How much did RCUS raise in its IPO?
Compare RCUS Stock to Peers. Symbol. Last Price. Market Cap. % Δ 1 Yr. % Δ 5 Yr. RCUS. Arcus Biosciences, Inc. $33.70.
What are analysts' price targets for Arcus Biosciences' stock?
Apr 01, 2022 · According to 17 analysts, the average rating for RCUS stock is "Buy." The 12-month stock price forecast is 65.59, which is an increase of 73.84% from the latest price.
Is RCUS a good buy?
The consensus among 2 Wall Street analysts covering (NYSE: RCUS) stock is to Strong Buy RCUS stock.
Should I buy Arcus Biosciences stock?
There are currently 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Arcus Biosciences stock.
Is Arcus Biosciences a buy right now?
5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Arcus Biosciences in the last twelve months. There are c...
How has Arcus Biosciences' stock price been impacted by Coronavirus (COVID-19)?
Arcus Biosciences' stock was trading at $16.97 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Healt...
When is Arcus Biosciences' next earnings date?
Arcus Biosciences is scheduled to release its next quarterly earnings announcement on Wednesday, May 4th 2022. View our earnings forecast for Arcu...
How were Arcus Biosciences' earnings last quarter?
Arcus Biosciences, Inc. (NYSE:RCUS) posted its quarterly earnings data on Tuesday, February, 22nd. The company reported $3.71 earnings per share (E...
What price target have analysts set for RCUS?
5 brokerages have issued 1 year price objectives for Arcus Biosciences' shares. Their forecasts range from $43.00 to $100.00. On average, they expe...
Who are Arcus Biosciences' key executives?
Arcus Biosciences' management team includes the following people: Terry J. Rosen , Chairman & Chief Executive Officer ( LinkedIn Profile ) Juan...
What is Terry Rosen, Ph.D.'s approval rating as Arcus Biosciences' CEO?
4 employees have rated Arcus Biosciences CEO Terry Rosen, Ph.D. on Glassdoor.com . Terry Rosen, Ph.D. has an approval rating of 100% among Arcus B...
Who are some of Arcus Biosciences' key competitors?
Some companies that are related to Arcus Biosciences include Jazz Pharmaceuticals (JAZZ) , Dr. Reddy's Laboratories (RDY) , Biohaven Pharmaceuti...
What other stocks do shareholders of Arcus Biosciences own?
Based on aggregate information from My MarketBeat watchlists, some companies that other Arcus Biosciences investors own include Horizon Therapeuti...
How much does Arcus Biosciences make?
When will Arcus Biosciences release its earnings?
Arcus Biosciences has a market capitalization of $2.09 billion and generates $77.52 million in revenue each year. The company earns $-122,860,000.00 in net income (profit) each year or ($2.24) on an earnings per share basis.
About RCUS
Arcus Biosciences is scheduled to release its next quarterly earnings announcement on Thursday, August 5th 2021. View our earnings forecast for Arcus Biosciences.
Analyst Forecast
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States.
News
According to 11 analysts, the average rating for RCUS stock is "Strong Buy." The 12-month stock price forecast is 64.40, which is an increase of 119.95% from the latest price.
Signals & Forecast
HAYWARD, Calif.-- (BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that the Compensati...
Support, Risk & Stop-loss
The Arcus Biosciences Inc. stock holds buy signals from both short and long-term moving averages giving a positive forecast for the stock, but the stock has a general sell signal from the relation between the two signals where the long-term average is above the short-term average.
Is Arcus Biosciences Inc. stock A Buy?
On the downside, the stock finds support just below today's level from accumulated volume at $29.38 and $29.28. There is natural risk involved when a stock is testing a support level, since if this is broken, the stock then may fall to the next support level. In this case, Arcus Biosciences Inc. finds support just below today's level at $29.38.
Insiders are very positive buying more shares than they are selling in Arcus Biosciences Inc
Arcus Biosciences Inc. holds several positive signals, but we still don't find these to be enough for a buy candidate. At the current level, it should be considered as a hold candidate (hold or accumulate) in this position whilst awaiting further development.
Golden Star Signal
In the last 100 trades there were 8.45 million shares bought and 1.67 million shares sold. The last trade was done 71 days ago by Tang Carolyn C. who sold 225 shares. The large amount of stocks bought compared to stocks sold indicate that the insiders believe there is a potential good upside.
Top Fintech Company
This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star. This signal is rare and, in most cases, gives substantial returns. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day!
